DE69527204T2 - Behandlung von krebs durch verwendung von hsv-mutanten - Google Patents

Behandlung von krebs durch verwendung von hsv-mutanten

Info

Publication number
DE69527204T2
DE69527204T2 DE69527204T DE69527204T DE69527204T2 DE 69527204 T2 DE69527204 T2 DE 69527204T2 DE 69527204 T DE69527204 T DE 69527204T DE 69527204 T DE69527204 T DE 69527204T DE 69527204 T2 DE69527204 T2 DE 69527204T2
Authority
DE
Germany
Prior art keywords
treating cancer
mutant
gamma
gene
hsv mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69527204T
Other languages
English (en)
Other versions
DE69527204D1 (de
Inventor
Roderick Maclean
Moira Brown
William Fraser
Paul Randazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Wistar Institute of Anatomy and Biology
Original Assignee
University of Glasgow
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69527204(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Glasgow, Wistar Institute of Anatomy and Biology filed Critical University of Glasgow
Application granted granted Critical
Publication of DE69527204D1 publication Critical patent/DE69527204D1/de
Publication of DE69527204T2 publication Critical patent/DE69527204T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69527204T 1994-07-29 1995-07-28 Behandlung von krebs durch verwendung von hsv-mutanten Expired - Lifetime DE69527204T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment
PCT/GB1995/001791 WO1996003997A2 (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant

Publications (2)

Publication Number Publication Date
DE69527204D1 DE69527204D1 (de) 2002-08-01
DE69527204T2 true DE69527204T2 (de) 2003-02-20

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527204T Expired - Lifetime DE69527204T2 (de) 1994-07-29 1995-07-28 Behandlung von krebs durch verwendung von hsv-mutanten

Country Status (12)

Country Link
US (3) US7674468B2 (de)
EP (2) EP1192948A3 (de)
JP (2) JP4321723B2 (de)
AT (1) ATE219681T1 (de)
AU (1) AU3119995A (de)
CA (1) CA2196315C (de)
DE (1) DE69527204T2 (de)
DK (1) DK0773785T3 (de)
ES (1) ES2179880T3 (de)
GB (1) GB9415320D0 (de)
PT (1) PT773785E (de)
WO (1) WO1996003997A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
CA2370187C (en) 1999-04-15 2011-08-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
MXPA02002142A (es) * 1999-08-31 2003-04-10 Gen Hospital Corp Promotor especifico de la celula y/o especifico del tumor, que re-selecciona como objetivo la expresion del gen gamma 35.5 de herpes.
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2441663C (en) 2001-03-27 2013-01-22 Medigene, Inc. Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2004216928B2 (en) 2003-03-07 2007-03-08 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
DK1606411T3 (da) 2003-03-27 2009-03-30 Ottawa Health Research Inst Mutant vesikulær stomatitis-vira og anvendelse deraf
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
KR101479093B1 (ko) 2005-03-07 2015-01-26 로바츠 리서치 인스티튜트 M135r 결핍 점액종 바이러스 및 이의 치료학적 용도
CN105769931B (zh) 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
EP3380621A4 (de) * 2016-04-22 2019-05-08 Immvira Co., Limited Konstruktion des vektors von obligaten onkolytischen herpes-simplex-viren (ohsv) und konstrukte zur krebstherapie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
EP0675961B1 (de) 1992-03-31 2002-11-27 Arch Development Corporation Behandlung von Tumorerkrankungen mit modifiziertem HSV
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6139834A (en) 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0862445B2 (de) 1995-10-06 2017-03-22 Arch Development Corporation Kombination von Herpes simplex Virus und Chemotherapie für Krebstherapie
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
WO2007132169A1 (en) 2006-05-11 2007-11-22 Crusade Laboratories Limited Mutant hsv, materials and methods for generation of mutant hsv
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
WO1996003997A2 (en) 1996-02-15
EP0773785A2 (de) 1997-05-21
JPH10503766A (ja) 1998-04-07
ES2179880T3 (es) 2003-02-01
ATE219681T1 (de) 2002-07-15
EP1192948A2 (de) 2002-04-03
PT773785E (pt) 2002-11-29
US20100172872A1 (en) 2010-07-08
CA2196315C (en) 2010-02-09
JP4321723B2 (ja) 2009-08-26
WO1996003997A3 (en) 1996-05-02
GB9415320D0 (en) 1994-09-21
US8067012B2 (en) 2011-11-29
US20120141418A1 (en) 2012-06-07
DK0773785T3 (da) 2002-10-07
EP1192948A3 (de) 2002-09-04
DE69527204D1 (de) 2002-08-01
CA2196315A1 (en) 1996-02-15
EP0773785B1 (de) 2002-06-26
US7674468B2 (en) 2010-03-09
AU3119995A (en) 1996-03-04
JP2008037869A (ja) 2008-02-21
US20050260169A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
DE69527204D1 (de) Behandlung von krebs durch verwendung von hsv-mutanten
FI853622A0 (fi) Diarylacetylener, deras framstaellning och anvaendning.
EP0290133A3 (de) Ternar-Photoinitiatorsystem für Additionspolymerisation
DE69232782D1 (de) Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
EP0377191A3 (de) Strahlungsempfindliches, ethylenisch ungesättigte, copolymerisierbare Verbindungen und Verfahren zu deren Herstellung
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
MY123980A (en) Photoresist compositions comprising polycyclic polymers with acid labile pendant groups
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
DK0642530T3 (da) Dolastatinderivater
EP0389428A3 (de) N,N-Bis(1-hydroxycarbyloxy-2,2,6,6-tetramethyl-piperidin-4-yl) aminotriazine und damit stabilisierte Mischungen
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DK0589949T3 (da) Hidtil ukendte peptider, fremgangsmåder til fremstilling heraf og anvendelse af disse
DE69327338T2 (de) Cycloaliphatische acryloyl-monomere
ATE41940T1 (de) Wasserloesliche copolymerisate und deren verwendung als baustoffhilfsmittel.
DE3689853D1 (de) Verwendung von Gyrasehemmern zur Dekontamination von Mycoplasma-infizierten Zellkulturen.
FI882444A (fi) Substituerade vinylkefalosporiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
SE9303503D0 (sv) Acrylic Monomer
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
ATE34987T1 (de) Neue antibiotika, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und zwischenprodukte zu ihrer herstellung.
BR9407232A (pt) Compostos de tiocarbamoíla
SG42686G (en) 1,3/diaza-9-thia-anthracene-2,4-diones and photopolymerisable mixture containing these compounds
EP0563814A3 (de)
ATE46264T1 (de) Thymidinkinase-negativ-temperaturbestaendiger rinder herpes-virus-1-mutant als vakzin gegen infektioese rinder-rhinotracheitis.
UA19315A (uk) Тіатрикарбоціаhіhові барвhики як спектральhі сеhсибілізатори фотографічhих емульсій до області спектра 830-860 hм

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings